EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost‐Effectiveness of Fracture Prevention in Postmenopausal Women With Early Breast Cancer in China

Jin-Yu Liu, Xi-Han Lin, Yi-Han Chen, Lin Wang, Ting Liu, Yu Zhang, Takahiro Mori, Kensuke Moriwaki, Ru-Xu You iD

Journal of Cachexia, Sarcopenia and Muscle · 2025

DOI: 10.1002/jcsm.70161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Jin-Yu Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Breast Neoplasms, Fractures, Bone. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Pharmaceutical Association Hospital Pharmacy department, Hubei Provincial Natural Science Foundation Joint Fund for Innovation and Development, the Specialized Research Program for Post-market Clinical Research of Innovative Drugs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aromatase inhibitors (AIs) significantly increase the risk of osteoporosis and related fractures in postmenopausal women with hormone receptor (HR)–positive early breast cancer (EBC), posing a substantial clinical and economic burden. Effective fracture prevention strategies are critical, especially in resource‐constrained settings such as China.

Methods

A Markov microsimulation model was developed to evaluate the cost‐effectiveness of fracture prevention strategies for 60‐year‐old postmenopausal women with HR‐positive EBC treated with AIs in China. Six strategies were compared: (a) no intervention, (b) one‐time bone mineral density (BMD) screening followed by anti‐osteoporotic medication for patients with osteoporosis or osteopenia, (c) annual BMD screening followed by anti‐osteoporotic medication for patients with osteoporosis or osteopenia and (d) universal anti‐osteoporotic medication without prior BMD screening. Outcomes included incremental cost‐effectiveness ratios (ICERs) per quality‐adjusted life‐year (QALY) gained versus China's willingness‐to‐pay (WTP) threshold (3 × GDP/capita = $38 223/QALY).

Results

All interventions reduced fractures but increased costs versus no intervention. For women aged 60–64 years, one‐time BMD screening followed by therapy for osteoporosis ( T ‐score ≤ −2.5) achieved an ICER of $17 368/QALY, below the WTP threshold. Annual screening yielded marginally higher QALYs (+0.0096) but higher costs (+$895.09), resulting in an ICER exceeding $38 223/QALY. For women ≥ 65 years, both one‐time screening for osteoporosis or osteopenia and universal therapy were cost‐effective. Universal therapy dominated in high‐risk subgroups (history of falls/fractures), achieving the highest QALY gains.

Conclusions

One‐time BMD screening with selective alendronate for osteoporosis is cost‐effective for Chinese women aged ≥ 60 receiving AIs, aligning with China's healthcare constraints. Universal therapy becomes favourable for older or high‐risk subgroups. These data‐driven findings support tailored strategies to optimise bone health management and resource allocation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisBreast NeoplasmsFractures, BoneHumansFemaleChinaPostmenopauseMiddle AgedQuality-Adjusted Life YearsBone DensityMarkov ChainsAged

Stichwörter der Autor:innen

aromatase inhibitorsbreast cancercost‐effectiveness analysisfracture preventionosteoporosis

Autor:innen und Institutionen

  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.
  • Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki Prefecture, Japan.
  • Division of Health Policy and Management, Department of Biomedical Science, College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga Prefecture, Japan.

ORCID-Profile: Ru-Xu You

Förderung

  • Chinese Pharmaceutical Association Hospital Pharmacy department
  • Hubei Provincial Natural Science Foundation Joint Fund for Innovation and Development
  • the Specialized Research Program for Post-market Clinical Research of Innovative Drugs

Zitieren

APA

Liu, J. Y., Lin, X. H., Chen, Y. H., Wang, L., Liu, T., Zhang, Y., Mori, T., Moriwaki, K., & You, R. X. (2025). Cost‐Effectiveness of Fracture Prevention in Postmenopausal Women With Early Breast Cancer in China. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70161

Vancouver

Liu JY, Lin XH, Chen YH, Wang L, Liu T, Zhang Y, et al. Cost‐Effectiveness of Fracture Prevention in Postmenopausal Women With Early Breast Cancer in China. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.70161

BibTeX
@article{Liu2025,
  author = {Liu, Jin-Yu and Lin, Xi-Han and Chen, Yi-Han and Wang, Lin and Liu, Ting and Zhang, Yu and Mori, Takahiro and Moriwaki, Kensuke and You, Ru-Xu},
  title = {Cost‐Effectiveness of Fracture Prevention in Postmenopausal Women With Early Breast Cancer in China},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.70161}
}
Kostenlos starten →